The ARF tumor suppressor regulates bone remodeling and osteosarcoma development in mice

Keyphrases

• Adjuvant Therapy 10%
• Bisphosphonates 10%
• Bone Remodeling 100%
• Bone Turnover 10%
• Developmental Processes 10%
• Differentiation in Vitro 10%
• Genetic Predisposition 10%
• Intact Level 10%
• Long Bone 10%
• Loss of Heterozygosity 10%
• Master Regulator 10%
• Mature Osteoblasts 10%
• Mice Transgenic 10%
• Net Increase 10%
• New Bone 10%
• Oncogene 10%
• Osteoblast 30%
• Osteoblast Functions 10%
• Osteoblast Markers 20%
• Osteoclast 20%
• Osteoclast Activation 10%
• Osteoclast Activity 20%
• Osteolytic Lesions 10%
• Osteosarcoma 100%
• P53 mRNA 10%
• Primary Tumor 10%
• Process Independent 10%
• Repressor 10%
• Ribosomal Biogenesis 10%
• Through Effect 10%
• Trabecular Bone Volume 10%
• Transcript Level 10%
• Tumor 40%
• Tumor Suppressor 100%
• Well-differentiated 10%
• Zoledronic Acid 10%

Biochemistry, Genetics and Molecular Biology

• Biogenesis 16%
• Bone Mass 16%
• Bone Remodeling 100%
• Bone Turnover 16%
• Genetic Predisposition 16%
• Loss of Heterozygosity 16%
• Messenger RNA 16%
• Oncogene 16%
• Osteoblast 100%
• Osteoclast 33%
• Osteoclast Activity 50%
• P53 50%
• Repressor 16%
• Transgenic Mouse 16%
• Tumor Suppressor Protein 100%

Pharmacology, Toxicology and Pharmaceutical Science

• Bisphosphonic Acid Derivative 10%
• Bone Atrophy 10%
• Genetic Predisposition 10%
• Lymphoma 10%
• Messenger RNA 10%
• Neoplasm 30%
• Osteosarcoma 100%
• Primary Tumor 10%
• Protein P53 30%
• Transgenic Mouse 10%
• Tumor Suppressor Protein 100%
• Zoledronic Acid 10%